WallStreetZenWallStreetZen

NASDAQ: BNGO
Bionano Genomics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BNGO

Based on 1 analyst offering 12 month price targets for Bionano Genomics Inc

Min Forecast
$6.00+387.8%
Avg Forecast
$6.00+387.8%
Max Forecast
$6.00+387.8%

Should I buy or sell BNGO stock?

Based on 1 analyst offering ratings for Bionano Genomics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BNGO stock forecasts and price targets.

BNGO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-13

1 of 1

Forecast return on equity

Is BNGO forecast to generate an efficient return?

Company
-10.64%
Industry
23.45%
Market
167.78%
BNGO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BNGO forecast to generate an efficient return on assets?

Company
-7.07%
Industry
16.95%
BNGO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BNGO earnings per share forecast

What is BNGO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.36
Avg 2 year Forecast
-$0.99
Avg 3 year Forecast
-$0.53

BNGO revenue forecast

What is BNGO's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$32.8M+8.63%
Avg 2 year Forecast
$44.2M+46.36%
Avg 3 year Forecast
$55.9M+85.22%
BNGO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BNGO revenue growth forecast

How is BNGO forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
22.81%
Industry
8.38%
Market
13.3%
BNGO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BNGO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BNGO vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
BNGO$1.23$6.00+387.80%Buy
RGNT$2.23N/AN/A
CUPR$2.91N/AN/A
RVP$0.72N/AN/A
FEMY$2.71$10.00+269.00%Strong Buy
View Top Medical Stocks

Bionano Genomics Stock Forecast FAQ

Is Bionano Genomics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BNGO) stock is to Buy BNGO stock.

Out of 1 analyst, 0 (0%) are recommending BNGO as a Strong Buy, 1 (100%) are recommending BNGO as a Buy, 0 (0%) are recommending BNGO as a Hold, 0 (0%) are recommending BNGO as a Sell, and 0 (0%) are recommending BNGO as a Strong Sell.

If you're new to stock investing, here's how to buy Bionano Genomics stock.

What is BNGO's earnings growth forecast for 2026-2028?

(NASDAQ: BNGO) Bionano Genomics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 30.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.

Bionano Genomics's earnings in 2026 is -$32,162,000.On average, 4 Wall Street analysts forecast BNGO's earnings for 2026 to be -$27,748,967, with the lowest BNGO earnings forecast at -$28,738,235, and the highest BNGO earnings forecast at -$26,339,261. On average, 3 Wall Street analysts forecast BNGO's earnings for 2027 to be -$11,652,164, with the lowest BNGO earnings forecast at -$11,195,216, and the highest BNGO earnings forecast at -$11,994,875.

In 2028, BNGO is forecast to generate -$6,246,521 in earnings, with the lowest earnings forecast at -$6,001,559 and the highest earnings forecast at -$6,430,242.

What is BNGO's revenue growth forecast for 2026-2028?

(NASDAQ: BNGO) Bionano Genomics's forecast annual revenue growth rate of 22.81% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.3%.

Bionano Genomics's revenue in 2026 is $30,176,000.On average, 4 Wall Street analysts forecast BNGO's revenue for 2026 to be $386,050,060, with the lowest BNGO revenue forecast at $367,018,428, and the highest BNGO revenue forecast at $401,572,146. On average, 3 Wall Street analysts forecast BNGO's revenue for 2027 to be $520,142,982, with the lowest BNGO revenue forecast at $499,745,218, and the highest BNGO revenue forecast at $535,441,305.

In 2028, BNGO is forecast to generate $658,228,307 in revenue, with the lowest revenue forecast at $632,413,123 and the highest revenue forecast at $677,589,695.

What is BNGO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BNGO) forecast ROA is -7.07%, which is lower than the forecast US Medical Instruments & Supplies industry average of 16.95%.

What is BNGO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BNGO price target, the average BNGO price target is $6.00, with the highest BNGO stock price forecast at $6.00 and the lowest BNGO stock price forecast at $6.00.

The Wall Street analyst predicted that Bionano Genomics's share price could reach $6.00 by Apr 13, 2027. The average Bionano Genomics stock price prediction forecasts a potential upside of 387.8% from the current BNGO share price of $1.23.

What is BNGO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BNGO) Bionano Genomics's current Earnings Per Share (EPS) is -$3.02. On average, analysts forecast that BNGO's EPS will be -$2.36 for 2026, with the lowest EPS forecast at -$2.44, and the highest EPS forecast at -$2.24. On average, analysts forecast that BNGO's EPS will be -$0.99 for 2027, with the lowest EPS forecast at -$0.95, and the highest EPS forecast at -$1.02. In 2028, BNGO's EPS is forecast to hit -$0.53 (min: -$0.51, max: -$0.55).

What is BNGO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BNGO) forecast ROE is -10.64%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.